Results 201 to 210 of about 713,346 (360)

Indication of acid suppression therapy and predictors for the prophylactic use of proton-pump inhibitors vs. histamine-2 receptor antagonists in a Malaysian tertiary hospital

, 2015
Ai Ling Oh, Andrew G. Tan, Hui S. Phan, Basil C. Lee, Nafisah Jumaat, Soo P. Chew, S H Wong, Shee H. Ting, Theebaa Subramaniam   +8 more
openalex   +2 more sources

Influence of astemizole, an H1 receptor antagonist, on the locomotors activity of carbamazepine and valproate in mice [PDF]

, 2012
Mariusz Świąder, Katarzyna Świąder
openalex   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist. [PDF]

JAAD Case Rep
Mooney N, Grewal A, Pei S, Bogner P, Kuraitis D.   +4 more
europepmc   +1 more source

PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.

, 1990
Z. Wiesenfeld‐Hallin, Xu Xiaohan, Joel W. Hughes, David C. Horwell, Tomas Hökfelt   +4 more
openalex   +2 more sources

The Effect of Detergent on Human Mu-opioid Receptor (hMOR) Localization as a Function of Pretreatment with Agonist and Antagonist [PDF]

, 2009
Tianming Sun, Tanya E. S. Dahms
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Safety and Efficacy of the AMPA Receptor Antagonist Perampanel for Tremors: A Systematic Review. [PDF]

Acta Med Philipp
Manalo RVM, Dela Cruz JRC, Pasco PM.
europepmc   +1 more source

Derivatives of an endothelin A receptor antagonist for PET imaging [PDF]

, 2011

openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source